CapsoVision Inc Dossier
Qualitative Analysis
Business overview
CapsoVision, Inc. is a commercial-stage medical technology company specializing in the development of advanced imaging and artificial intelligence (AI) enabled capsule endoscopy solutions designed to identify abnormalities of the gastrointestinal (GI) tract. The company's flagship product, CapsoCam Plus®, is a wire-free, single-use capsule endoscope that features four laterally oriented onboard cameras capturing a complete 360-degree panoramic view of the small bowel mucosa. Unlike traditional capsule endoscopy systems that require patient-worn external receiver equipment, CapsoCam Plus stores video data internally, eliminating the need for external recorders and streamlining clinical workflows. This design supports a flexible, telemedicine-enabled workflow where patients can ingest the capsule at home under virtual medical supervision. CapsoVision also provides CapsoCloud, a secure cloud-based software-as-a-service portal for remote streaming, storage, and clinician review of capsule studies.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Developing and integrating in-house artificial intelligence capabilities across the capsule endoscopy portfolio. This includes submitting a 510(k) application for an AI-assisted reading module for CapsoCam Plus to enhance polyp detection sensitivity and reduce clinician review times.
Expected impact: Improves diagnostic accuracy, reduces physician workload, and establishes a competitive edge as the only capsule endoscopy company with in-house AI core competency.
Prioritizing resources toward a second-generation CapsoCam Colon capsule featuring improved imaging and AI capabilities, following FDA feedback on the first-generation system. The initiative is supported by an expanded pivotal study arm of approximately 800 patients across up to 20 U.S. sites.
Expected impact: Enables non-invasive colon imaging and polyp detection, serving as a major future growth driver.
Advancing the CapsoCam UGI capsule endoscopy system designed for early-stage pancreatic ductal adenocarcinoma detection. The company applied for FDA Breakthrough Device Designation in late 2025 to expedite development.
Expected impact: Expands diagnostic capabilities beyond small bowel examinations into high-impact oncology screening.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborating to develop custom complementary metal-oxide-semiconductor (CMOS) image sensor samples. These upgraded sensors are intended to be integrated into future generations of CapsoVision's capsule endoscopes to enhance imaging performance and support clinical evaluations.
Terms: Originally a $4.1 million development fee (comprising a $1 million initial cash payment and $3.1 million tied to milestones). Amended on March 9, 2026, to increase the total fee by $1 million to approximately $5.1 million to cover enhanced specification features.